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Gastroesophageal reﬂux disease is mediated principally by acid. Today, we recognise reﬂux reaches beyond the esophagus, where
pepsin, not acid, causes damage. Extraesophageal reﬂux occurs both as liquid and probably aerosol, the latter with a further reach.
Pepsin is stable up to pH 7 and regains activity after reacidiﬁcation. The enzyme adheres to laryngeal cells, depletes its defences,
and causes further damage internally after its endocytosis. Extraesophageal reﬂux can today be detected by recognising pharyngeal
acidiﬁcation using a miniaturised pH probe and by the identiﬁcation of pepsin in saliva and in exhaled breath condensate by a
rapid, sensitive, and speciﬁc immunoassay. Proton pump inhibitors do not help the majority with extraesophageal reﬂux but
speciﬁcally formulated alginates, which sieve pepsin, give beneﬁt. These new insights may lead to the development of novel drugs
that dramatically reduce pepsinogen secretion, block the eﬀects of adherent pepsin, and give corresponding clinical beneﬁt.
“For now we see through a glass, darkly.”—First epistle, Chapter 13, Corinthians
1.Introduction
T h i sq u o t a t i o nf r o mt h eB i b l e ,o f t e nu s e di nd r a m aa n d
thrillers, symbolises “that the clarity of a situation is often
obscured”. It is in our view an apt description of the
syndrome we today recognise as extraesophageal reﬂux
(EER). The inspired insight in the 1990s that the symptoms
and ﬁndings might constitute a distinct entity [1]w a s
followed by growing awareness in the last decade that
the underlying cause was gastroesophageal reﬂux. Hence,
the Montreal classiﬁcation included several extraesophageal
features within the spectrum of gastroesophageal reﬂux
disease (GERD), the association considered “established” for
laryngeal symptoms, cough, and asthma (and “proposed”
for recurrent otitis media, idiopathic pulmonary ﬁbrosis,
pharyngitis, and sinusitis) [2]. This was a remarkable
foresight, for at the time, the data on which we today regard
for EER was still emerging. Today, however, there is strong
evidence that laryngeal damage from EER is mediated by
pepsin. This decade may see these discoveries lead to clearer
understanding of the disease process and consequently lead
to the development of eﬀective therapy.
The earlier confusion surrounding the entity of EER and
the story now unfolding is reminiscent of the early 1980s
when an unusual organism came to be identiﬁed in the
stomach, particularly in those with peptic ulcer. Looking
back, it may seem self-evident that Helicobacter pylori (H.
pylori) was closely related to the development of duodenal
ulcer (DU)—but it certainly did not seem so at the time.
1.1. Acid—and Beyond. GERD has, with good reason, been
widely regarded as the consequence of excessive reﬂux from
the stomach into the lower esophagus, the acid component
of the reﬂuxate damaging the esophageal mucosa. This link
is made indelible in the clinician’s mind by the rapid and
sometimes dramatic relief proton pump inhibitors (PPIs)
give, through profound acid suppression. Today, we are
increasingly aware reﬂux can reach much further, extending
beyond the upper esophagus into the pharynx, larynx,2 International Journal of Otolaryngology
airways, and middle ear, and may damage these structures
[3, 4].
The beneﬁts of the PPIs are striking in patients with
typical GERD, that is, those with lower esophageal symp-
toms, principally retrosternal burning (“heartburn”), and
regurgitation (the two together commonly referred to as
the “classical symptoms” of reﬂux) with or without erosive
esophageal changes. This is reﬂected by numerous clinical
trials and reinforced by worldwide experience [5, 6]. In
contrast, PPIs generally give little beneﬁt when symptoms
arisefromreﬂuxate-damagedorgansfurtheraway,indicating
that unlike in the esophagus, acid may not be the damaging
agent. In EER, the damaging agent we suggest is pepsin (and
perhaps bile acids).
Pepsin is produced only in the stomach; hence evidence
of its presence in these organs signiﬁes reﬂuxate has reached
them. The enzyme has recently been identiﬁed within the
laryngeal epithelium, in the saliva of patients with suspected
reﬂux laryngitis, and in the exhaled breath of those with
airways and lung disease, where reﬂux is thought to have
played a part. Pepsin has also been found in the middle ear
in otitis media eﬀusions (where bile acids, too, have recently
been identiﬁed).
“Host factors” too are presumably involved which inﬂu-
ence who develops disease and how severe it becomes.
These factors may also have a bearing whether the disorder
manifests with typical reﬂux symptoms arising from the
esophagus or as EER. Many with EER have little or no
retrosternalburningorregurgitation;thisissurprising,forto
reachtheextraesophagealareas,thereﬂuxatewouldﬁrsthave
to travel through the esophagus. Reﬂuxate is liquid, but there
is growing awareness that it may also be an aerosol. Firm
evidence is, however, yet to emerge. Nevertheless, an aerosol
remains an “attractive” possibility for it would account for
observations as yet unexplained. For example, intuitively, it
would seem that the concentration of hydrogen ions would
be less in an aerosol (compared to that in liquid reﬂuxate),
perhaps below a threshold to trigger esophageal symptoms.
The concept of pepsin and bile acids playing a role
in reﬂux disease developed many years ago but has been
often overlooked in recent times, as the very success of PPIs
increasingly focused attention on acid (to the exclusion of
other factors) but also in part because the relevant literature
is not usually referred to by gastroenterologists.
2. Aim
The aim of this paper is, therefore, to draw the key evidence
together and to raise awareness of EER amongst gastroen-
terologists, who today are increasingly invited by ENT and
respiratory specialists to help investigate patients in whom
this condition is suspected. Bile acids are mentioned but the
focus is on pepsin; GERD is often referred to but mainly to
compare and contrast with EER, the main thrust.
We have broadly adhered to the philosophy of the
Montreal classiﬁcation of GERD, [2] departing only when
it does not suﬃciently accommodate more recent ﬁndings
and evolving concepts of pathophysiology. Thus, a degree of
reﬂux into the lower esophagus and without any symptoms
is regarded as physiological gastroesophageal reﬂux (GER).
Gastroesophageal reﬂux disease (GERD) is the term applied
when reﬂux is accompanied by typical symptoms, with or
without erosive mucosal damage. At this stage, the total
duration of esophageal acid exposure is considerably longer
than in physiological reﬂux. Whilst extraesophageal reﬂux
disease is increasingly recognised, relatively little is known if
“physiological” extraesophageal reﬂux (EER) occurs.
3. History
3.1. GERD: A New Concept Emerges. In 1934, Asher Winkel-
stein ﬁrst raised the possibility that the symptoms in ﬁve
of his patients might have arisen from peptic esophagitis, a
condition resulting “from the irritant action on the mucosa
of hydrochloric acid and pepsin” [7–9]. From the late 1950s,
elegantexperimentalstudieshavedemonstratedthecomplex
interrelationshipbetweenbileacids,pepsinandhydrochloric
acid (HCl) interacting and leading to esophageal damage.
3.2. Shifting Perceptions. The role of these nonacid factors,
however, appeared to diminish in the clinician’s percep-
tion when the histamine H2 receptor antagonists (H2RA)
emerged in 1976. These were the ﬁrst drugs to powerfully
reduce acid secretion and proved highly eﬀective in con-
trolling peptic ulcer, thus demonstrating the central role of
acid in the disease process. By extension, it seemed likely to
also be of use in GERD, but the clinical beneﬁts proved to
be only modest. Acid inhibition, powerful with the H2RA,
was profound with the new class of drugs, the proton pump
inhibitors (PPIs), which became available in 1989. These
drugs proved markedly superior to H2RA in the treatment of
GERD, which reinforced the growing perception that it was
the acid component of reﬂuxed gastric contents that was the
cause of esophageal damage.
3.3. Pepsin and Bile Acids: At the Beginning
3.3.1. Pepsin. The elegant experimental studies of Goldberg
et al. [10] clearly demonstrated pepsin can damage the
esophagus. Cat esophagi were infused for an hour with HCl,
the pH ranging from 1 to 2.3. Acid at pH 1 proved very
damaging, whereas at pH 2.3 was without eﬀect; adding
pepsin to each of these infusates caused no further damage.
In the intermediate acidity range of pH 1.6 and 2.0, however,
the damage was proportional to the amount of pepsin added
(25 and 50µg/mL). Blocking the enzyme eﬀect by ﬁrst
premixing with amylopectin sulphate (a synthetic pepsin
inhibitor) protected the esophagus, thereby conﬁrming that
pepsin can, in the appropriate circumstances, cause damage.
HCl at pH 1 is probably not encountered in the gastric
lumen (other than in exceptional circumstances), for the
secreted acid is rapidly diluted. A pH of 1.6–3 is common,
however, and it is in this range when gastric reﬂuxate con-
taining acid and pepsin is most damaging to the esophageal
mucosa. Pepsinogen arises from the gastric peptic cells (also
called the chief cells) which share space in the same glands
as the acid-secreting parietal cells: the two secretions are
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Reﬂux, therefore, irrespective of its pH, always contains
pepsin (see below).
3.3.2. Bile Acids. Experimental studies in the 1980s demon-
strated the role of bile acids in damaging the esophageal
mucosa. In a series of studies by Harmon and colleagues
[11]a n db yS c h w e i t z e re ta l .[ 12], varying concentrations of
taurine-conjugated and unconjugated bile salts were infused
into rabbit esophagi at pH 2, 5 and 7. Signiﬁcant disruption
of the esophageal mucosal barrier occurred at bile acid
concentrations similar to those in the stomach of patients
with esophagitis [13]. The evidence, however, suggested that
such disruption was probably not the direct eﬀect of bile
acids solubilising the cell membrane phospholipids. Instead,
bile acids enter the epithelial cells and disrupt cellular
machinery from within, hence interfere with the cell barrier
function. Such entry is determined by the physicochemical
properties of the bile acids. Taurine-conjugates have a pKa of
∼2 that is, half the molecules are in solution at pH 2 and,
being charged, cannot penetrate the lipid bilayer of the cell
membrane. As the pH progressively rises, more bile acids
come out of solution and by pH 7 are insoluble, lose their
charge and as a result can now enter the epithelial cells.
These experimental studies have particular clinical rele-
vance, for bile is present in esophageal reﬂuxate [14–16]a n d
is most frequently noted in patients with severe esophagitis
or complicated Barrett’s esophagus [17, 18] in whom it is
present at high concentrations [19].
3.4.ConceptualizingtheMechanismofDamage. Puttingthese
observations together, one can conceptualise circumstances
where pepsin in the reﬂuxate disrupts the esophageal
mucosal barrier by acting on the epithelial cell surface, whilst
bileacidsachievethesameeﬀectbydiﬀusingintothecelland
damaging from within.
These seemingly complex mechanisms contrast sharply
from the “corrosive” action of acid, an eﬀect “simpler” to
picture. Gastric acid consists of H+ and Cl− ions in water.
When in high concentrations, intuitively, the ﬂuid is more
“corrosive”; hence, the longer the time in contact with the
esophagus, the greater the likelihood it will damage the
mucosa. Conversely, lower concentrations are less damaging.
Importantly, the basic constituents of acid are unchanged,
only its concentration.
4.Pepsin:Nature,Activation,Acidity,and
Enzyme Activity:ClinicalSigniﬁcance
4.1. Nature and Activation. Pepsin is an ancient molecule
and present in all vertebrates studied, such as ﬁshes and
mammals. The stomach is largely devoid of live organisms
(with the exception of H. pylori), a state widely believed
to result from the presence of gastric acid, which acts as a
“bulk steriliser”. A second important action of acid is the
activation of pepsinogen. This releases pepsin which initiates
digestion through proteolysis, an action which also probably
helps keep the stomach free of most bacteria [20].
The peptic chief cells produce and store pepsinogen,
the precursor of the active enzyme. Pepsin, an aspartic
proteinase, is a large bilobed molecule and concave on one
surface, the concavity occupied by the detachable pro-part.
When in contact with acid, the pro-part detaches exposing
the concavity, the active site for enzyme action. The enzyme
attaches to its substrate at this point and cleaves it. Acid (pH
< 6) is required to convert inert pepsinogen to active pepsin
but once converted, the pepsin continues the autocatalytic
process sustaining the cascade in the absence of acid [3].
4.2. Pepsin: Isoenzymes. Pepsin has traditionally been stud-
ied by gel electrophoresis of gastric juice and tissue
homogenates, which typically shows eight zones of lysis to
which various names and designations have been applied
based on their electrophoretic mobility [21, 26]. The pattern
reﬂects the fact that pepsin is not a single molecule but
encompasses a family of isoenzymes which structurally are
similar. Today, the pepsin isoenzymes in gastric juice can be
separated by high-performance anion exchange chromatog-
raphy (HPAEC) using chloride counter ion gradient elution
(Figure 1). Each pepsin isoenzyme has its own “optimal
pH level” when its action is at a maximum, thus ensuring
digestion across a wide range of gastric pH (see Table 1).
4.3. Pepsin: pH and Stability. The activity and stability of the
enzyme is closely related to the prevailing pH of its environ-
ment, a relationship investigated over the last 40 years using
diﬀerent sources of pepsin, various substrates, and changing
analytical methods. The results were broadly similar, and
diﬀerences were attributed to the experimental conditions.
Recent studies reexamining the pH-pepsin relationship in
conditions of low acidity have given important new insights
into enzyme stability and activity which have major clinical
signiﬁcance (and are discussed in detail further on).
Individual pepsin isoenzymes were noted to be stable
for 24 hours even at body temperature but were ultimately
degraded by autocatalysis if stored at its pH optima. In
contrast, a mixture of isoenzymes, as would be found in
gastric secretion, proved to be more stable [22].For example,
puriﬁed porcine pepsin was irreversibly denatured at pH 7.1,
whereas peptic activity of human gastric juice persisted until
exposed to pH 7.8. [27]. A “dormant” phase was observed
betweenpH6and8whentheenzymewasinactivebutintact,
hence it could be activated on return to pH <6[ 28].
4.4. Pepsin: pH and Enzyme Activity: The Traditional View. It
has long been known that pepsin is at its most active at pH
2 to 3, and activity is declining as acidity diminishes [29].
Emerging evidence has shown that reﬂuxate reaching the
extraesophageal areas is characterised by low acidity or none
at all in those on high-dose PPI treatment. Such conditions
have been widely regarded to destroy pepsin or to render it
inactive, hence the scepticism that pepsin played a signiﬁcant
roleindamagingextra-esophagealtissues.Recently,however,
important new information challenges such beliefs.
4.5. Pepsin: pH and Enzyme Activity: The Emerging Evidence.
This interrelation has recently been reassessed, now using
pepsin isoenzyme 3B puriﬁed from human gastric juice
[30]. It is the largest fraction of pepsin and accounts for
70% of the total enzyme eﬀect (Table 1), for which it serves4 International Journal of Otolaryngology
Inject Pepsin 5 3c 3b 3a
Time
1
Composition
Pepsin
5
3c
3b
3c
1
16.7
6.9
66.3
9.5
0.6
(µg)
72
30
286
41
2.5
(%)
A 280mm
Figure 1: Example of pepsin proﬁle from human gastric juice puriﬁed by HPAEC.
Table 1: The active pepsin isoenzymes in man.
Pepsin isoenzyme Proportion of total
pepsin
Substrate: pH optimum
range
Molecular
weight (Da) Comments
1 <5%
Haemoglobin: 1.9
Collagen: 3.0
Mucin: 2.0
43810
T h ep r o p o r t i o no fp e p s i n1r i s e st o2 3 %i nD U
Mucolytic pepsin
Complexed with carbohydrate
2 <1% Haemoglobin: 2.1 39950
3 80% Haemoglobin: 2.4–3.1 37150 Pepsin 3 is a complex of isoenzymes. The assay
measures their combined eﬀects.
3A
3B
3C
6%
70%
4-5% Haemoglobin: 3.2 3A is structurally similar to 3B but is
phosphorylated
5 (Gastricsin) 6-7%
Haemoglobin: 2.0–3.6
(maximum at 3.2)
Mucin: 3.5–5
31620 Stable up to pH 7.3
“Pepsin 4” is a complex of pepsin and an inhibiting peptide, hence, it does not appear in the list of active pepsin isoenzymes.
“Pepsin 6” is the remnant of a zymogen, in all probability pepsinogen, hence it too does not feature in the isoenzyme list.
“Zone 7” was found to be a cathepsin.
References [21–25].
as a good marker. The assay conditions were designed
to resemble those that might be expected in the human
larynx in laryngopharyngeal reﬂux (LPR), namely, little
or no acidity (pH 6.8), when pepsin would be inactive
unlessreactivatedbysubsequentacidicreﬂux.Theenzymatic
activity was measured by the rate of hydrolysis of a synthetic
peptide substrate. The isoenzyme activity was at ∼80% of its
maximum when measured at pH 1.5 and reached its peak
at pH 2. Thereafter, it declined to ∼45% at pH 4.5, ∼40%
at pH 5, fell to ∼10% at pH 6, and ceased altogether by pH
6.5. The stability of the isoenzyme was then explored having
ﬁrst incubated it at 37◦C for 24 hours at various pH levels,
ranging from 2 to 8, and assaying at pH 3.0. The enzyme
stored at pH 7.0 was inactive but stable, evidenced by the
observation that ∼80% of its activity was recovered when
reassayed at pH 3.0.
4.6. PPI Treatment: Eﬀe c to nP e p s i nC o n c e n t r a t i o n .Numer-
ous studies in man have examined the eﬀect of PPIs on
gastric acid secretion but only few on pepsin. An example
is a study on the eﬀect of high-dose omeprazole (60mg
daily for nine days) in eight healthy volunteers in whom the
volume of gastric secretion and output of acid and pepsin
wasmeasured[31].Acidsecretionfellmarkedlyfromamean
of 5.4 to 0.3mmol/h, and the volume decreased substantially
from 132 to 36mL/h. The mean pepsin output, however,International Journal of Otolaryngology 5
fell only modestly, from 126 to 101mg/h, but because of the
reduced volume, its concentration rose from 90mg to 290mg
per 100mL.
Thisstudy,likemostothersongastricsecretion,reliedon
the measurement of stomach contents aspirated through a
nasogastric tube. A novel noninvasive approach was recently
usedtomeasuregastricvolumebymagneticresonanceimag-
ing [32]. Unlike the study cited earlier [31], the reduction
in the volume of gastric secretion on PPI was only 12%,
hence the concentration of pepsin would have increased only
slightly.Theclinicalsigniﬁcanceofthesecontrastingﬁndings
is discussed further on.
4.7. PPI Treatment: pH, Pepsin Activity, and H. Pylori.
The PPIs commonly used today (e.g., omeprazole) on
conventional dosing (single 20mg dose in the morning) can
elevate gastric pH to ≥6 but only for short periods; for much
of the time, the pH is around 4 to 5 [6] and falls at night
whenacidsecretionbreaksthrough.Thus,forthemajorityof
24 hours, pepsin in gastric juice is still active or dormant but
stable, hence capable of reactivation when acidity returns.
High-dose PPI treatment (e.g., omeprazole 40mg twice
daily) has a greater eﬀect and is longer lasting, and the newer
PPIs (e.g., tenatoprazole) [33] may enhance this. These
conditions may keep pepsin inactive, but it seems unlikely
that the pH will be elevated to levels which will result in any
substantial degradation of the enzyme.
The presence of H. pylori increases the eﬀect of PPI, a
feature sometimes overlooked yet likely to have a bearing
on the eﬃcacy of PPI therapy in the uninfected or in those
in whom the organism has been eradicated. Several studies
conﬁrm this, an example being the seminal investigation
carried out in DU patients [34]. Here, the median 24-hour
intragastric pH when PPIs were not used was similar before
and after H. pylori eradication, 1.0 and 1.1, respectively. On
omeprazole 20mg, however, there was a major diﬀerence
in pH, 5.5 before eradication but only 3.0 after it. The
signiﬁcance is that whilst the majority of DU patients are
infectedwithH.pylori,itsprevalenceismuchlowerinGERD
patients (and similar to that in the general population),
hence theoretically, PPIs might have a lesser eﬀect.
4.8. PPIs, Pepsin, and Reﬂux: Clinical Signiﬁcance. PPI ther-
apy suppresses acid profoundly, has a variable eﬀect on the
volume of secretion (as indicated earlier) which is diﬃcult to
explain, but does not reduce the frequency of reﬂux episodes
[35]. When volume is reduced only slightly [32], much ﬂuid
remains in the stomach and is available to reﬂux, carrying
pepsintotheextraesophagealareas.Whenvolumeisreduced
substantially,theconcentrationofpepsinrises[31]butreﬂux
continues [35], although less is available to reﬂux, what
reaches the extraesophageal areas is rich in pepsin, hence is
damaging.
4.9. Pepsin, pH, and Cell Damage. Pepsin is reﬂuxed to the
extraesophageal areas where it adheres to the epithelium
[36]. If activated by acid in the reﬂuxate, it damages the
cells but even in the absence of acid the enzyme has the
capacity to damage, for, though dormant, it is stable. Two
mechanisms operate. The ﬁrst is by its reactivation when
exposed to acid in subsequent reﬂux episodes. The second
mechanism is independent of such reﬂux reacidiﬁcation: it is
taken up within epithelial cells by endocytosis and activated
from within [37]. This remarkable observation, based on
laryngeal cell studies, is a recent discovery with far reaching
consequences (and is discussed further on). The signiﬁcance
is that reﬂuxate always contains pepsin; even if devoid of acid
(as might happen on high dose PPI treatment), the enzyme
will still be damaging if reﬂux reaches the extraesophageal
areas.
4.10. PPIs and Pepsin: Potential Clinical Relevance. Based
on older studies, pepsin is commonly assumed to become
inactive at pH ≥4 and to be denatured at pH ≥5.5, hence
the widespread perception that PPI treatment renders the
enzyme inactive by elevating the gastric pH. This view, we
suggest,nowneedstobereadjustedtakingintoconsideration
the new evidence which clearly shows the enzyme retains
much of its activity at pH ≥4, is still intact up to nearly pH 8,
can be reactivated when exposed to acid once again but can
damage cells even in the absence of acid.
In clinical practice, PPIs will continue to be used in
EER, frequently in high dose, for they help some who in
addition to EER symptoms also have features of classical
GERD as well as the few who do not [38]. From the
evidence above, however, it seems unlikely that profound
acid suppression with PPIs as the sole treatment strategy
will give results comparable to those with typical esophageal
symptoms (heartburn and regurgitation) with or without
erosive esophagitis.
5.The Effectof Pepsinon EpithelialCells
In laboratory studies, pepsin swiftly breaks down protein,
the basis of its chemical assay. Its eﬀect on extraesophageal
tissues is in contrast subtle and perhaps sustained, depletes
the cells of its defences and threatens its viability. These
changes have been demonstrated in ongoing clinical and
laboratory studies by Johnston and colleagues who explored
the eﬀects of human pepsin 3B (puriﬁed from gastric juice)
onlaryngealepitheliumusingexvivosystemsandcellculture
studies [36, 37, 39, 40].
5.1. Pepsin: Entry into Epithelial Cells. Based on esophageal
and laryngeal biopsies from LPR patients and from control
subjects, and employing a variety of analytical methods,
they made three major observations: pepsin adhered to
epithelial cells, was endocytosed, and caused internal cell
derangements.
Pepsin was found adherent to the surface of laryngeal
epithelial cells obtained from LPR patients but not to those
f r o mc o n t r o ls u b j e c t s[ 36]; the absence in the latter group
is to be expected, for signiﬁcant reﬂux had already been
excluded by esophageal physiology studies. The enzyme was
not found adherent to the esophageal epithelium (in LPR
patients); this is surprising bearing in mind that to reach the
larynx the reﬂuxate has ﬁrst to travel along the length of the
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intercellular junctions and depletes proteins within the cell
involved in its defence (and is discussed further on).
Inactivepepsinistakenupwithinthecellsbyendocytosis
through a competitive receptor-mediated mechanism and is
found in vesicles located in the region of the Golgi system
[37].Suchendocytosis,thesecondobservation,issurprising,
for it seems unlikely that receptors speciﬁc for pepsin exist
in laryngeal tissues. Presumably, such receptors serve some
otherpurposebutwhenexposedtopepsin,they“shuttle”the
enzyme into the cells.
Whencellswereexposedtohumanpepsin3BatpH7.4,a
level at which the enzyme is inactive, several major changes,
nonetheless, occurred aﬀecting the inner cell structure and
function [39], the third major observation. The Golgi system
has a pH of ∼5.5, together with its associated endosomes
these process large molecules such as proteins and receptors
through its slightly acidic environment. The inference is that
the changes observed (see below) result from reactivation of
the dormant enzyme within the cell.
The cells swelled and structural damage to the mito-
chondria and to the Golgi system became visible on electron
microscopy within an hour and increased by 12 hours. The
early damage was accompanied by increased expression of
seven genes involved in cell stress and toxicity including
certain heat shock proteins (as a family, the production of
heat shock proteins is activated when the cell is stressed and
its survival threatened) and the late changes by the decreased
expression of another 18 such stress genes. The investigators
also used in parallel a cell toxicity assay which measures
mitochondrial activity in living cells. There was a signiﬁcant
increase in toxicity after pepsin exposure at pH 7.4 which
correlated well with the mitochondrial changes noted on
electron microscopy.
The evidence strongly argues for the following chain of
events: inactive pepsin is endocytosed, is activated within
the cells, and causes cell damage; this induces oxidative
stress and the accumulation of free oxygen radicals which,
in turn, damage mitochondria and may lead to cell death.
In the experimental system used, the cells were exposed only
once to pepsin, thus mimicking what might happen with an
isolated episode of LPR. Though damaged, the cells were still
viable at 12 hours but with repeated exposure, as would be
expected in chronic LPR, the damaged cells may not survive
[39].
5.2. Pepsin: Depletion of Cell Defences. The eﬀect of pepsin
was explored using a pig laryngeal epithelial cell model.
Humanpepsin3Bmarkedlydepletedcelldefencesonlywhen
the enzyme was made active by the presence of acid (pH
4). In contrast, acid on its own had no eﬀect, nor did the
enzyme when rendered inactive by raising pH to 7.4 or when
its activity was blocked with its inhibitor, pepstatin [30].
In a series of studies, the speciﬁc cell defence changes
noted were depletion of the carbonic anhydrase isoenzyme
CA3 and the stress protein Sep 70, reduction of E-cadherin,
and the alteration of the subtype proﬁle of protective mucin
produced [30, 36, 40, 41].
The isoenzyme CA3 is widely expressed in tissues,
including the basal layers of both esophageal and laryngeal
epithelium. It mediates the rapid two-way conversion of
CO2 and water to carbonic acid, bicarbonate, and H+,h e n c e
plays a key role in the regulation of cell pH. When the
esophageal epithelium is exposed to acid, the isoenzyme is
also expressed in the more superﬁcial cells, thus oﬀering
greaterprotectiontotheepitheliumnearestthereﬂuxedacid.
In contrast, its production remains limited to the basal layers
in the laryngeal epithelium.
Sep 70, like most other stress proteins, is a molecular
chaperone which regulates the correct folding and unfolding
of intracellular proteins during their passage through the
cell. E-cadherin is crucial for maintaining adhesion between
cells, and thereby mucosal integrity and its barrier function.
There are several subtypes of mucin, some more prominent
in speciﬁc tissues than others: collectively, they aﬀord pro-
tection. In chronic LPR, MUC-2, -3, and -5AC are amongst
the defensive mucins depleted, and in vitro studies conﬁrm
pepsin interferes with their production [42].
5.3. Tissue Damage in GER and EER: A Comparison. The
intensity of damage of the esophageal mucosa by acid reﬂux
(pH < 4) is proportional to the duration of contact. A
degree of reﬂux occurs in health, particularly after meals, but
peristalsis rapidly returns the reﬂuxate to the stomach; any
residue is neutralised by bicarbonate secreted in saliva and
by the esophageal mucus glands.
In striking contrast, the larynx and extraesophageal
structures have no mechanism for bulk removal of damaging
agents, hence they must rely on intracellular defences; but as
indicated earlier, such cell defences are much depleted after
exposure to reﬂux. Hence, even slight exposure to reﬂux can
cause disproportionate damage.
5.4. The Signiﬁcance of Dilated Intercellular Spaces in the
Squamous Epithelium. Acid injury to the esophageal squa-
mous epithelium results in the dilatation of the intercellular
spaces, which almost double in width; these changes are
visibleonlybyelectronmicroscopy.Thephenomenonisnow
well established in patients with both erosive and nonerosive
reﬂux disease [43, 44]. It was recently also observed in
healthy volunteers in whom the lower esophagus was infused
with only weak levels of acid (pH 5.5) that the changes
are no greater when strong acid (pH 2) with added pepsin
(±bile acid) was infused. The changes were widespread and
occurred not only at the site of infusion, but also well away
from it [45].
Such dilatation has been reproduced experimentally in
rabbit epithelium exposed to acid at pH 1.1 or at pH 2 but
with added pepsin [44]. These tissues had reduced electrical
resistance mainly due to “leakiness” of the paracellular path-
ways, the “leak” in proportion to the size of dextran particles
whichcouldenterthedamagedtissue.Thesigniﬁcanceisthat
the “leak” is physical not virtual.
These studies clearly show the sensitivity of the
esophageal epithelium to even low concentrations of acid.
Its possible relevance to EER comes from the observation
that dilatation of intercellular spaces has also been noted
in the laryngeal epithelium in patients with LPR [36, 46],
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attention. Whilst there is little acid in reﬂuxate reaching the
extraesophageal areas, it does contain pepsin, which may
potentially gain entry into the dilated spaces in the laryngeal
epithelium.
The nerve endings in the esophageal epithelium (in
monkeys) are located in the intercellular spaces and are
superﬁcial, appearing at a depth of only three cell layers,
a major ﬁnding [43]. These sensory nerves are thought
to be chemosensitive and respond to even low levels of
acid, pH 5.2 to 6.9, chronic irritation leading to secondary
hypersensitisation which perpetuates symptoms. The larynx,
too, is richly innervated and is exquisitely sensitive. A similar
train of events may, theoretically, occur in the larynx, which
prolongs the symptoms even when the stimulus is much
reduced.
5.5. Summary. In summary, esophageal mucosal damage is
mediated principally by acid, and laryngeal epithelial (and
possibly otherextraesophagealepithelium)damagebypepsin
(andpresumablyotheragents).TheenvironmentalpHinthe
larynx and hypopharynx is ∼5 . 5t o6 ,al e v e la tw h i c hp e p s i n
is only slightly active or dormant. Even when inactive, pepsin
damages cells after it is endocytosed and reacidiﬁed within
them. The enzyme adheres to the laryngeal epithelium and
when inactive is stable and can be reactivated by acidic reﬂux
evenwhentheepisodesareinfrequent.Theseadvancesinour
understanding perhaps explain the apparent paradox noted
in classical observations comparing EER and GER. As little
as three EER episodes per week can damage the larynx, it
was noted, whereas up to 50 GER episodes of acidic reﬂux
(pH < 4) per day can be seen in the asymptomatic individual
[1, 47].
6. The Reach andthe Natureof Reﬂux
6.1. Introduction. Reﬂux into the esophagus is usually imag-
ined as ﬂuid welling up from the stomach and/or spurting in
jets which sometimes reach high, a plausible interpretation
of pHmetry and impedance study results, the mental image
reinforced by artistic impressions in advertisements. For
gastroesophageal reﬂux to cause disease beyond the esoph-
agus, however, the reﬂuxate must self-evidently reach these
areas.
Reﬂux into the extraesophageal areas is not a new con-
cept. Almost two decades ago, Koufman [1] speculated on its
possibility as an explanation for chronic laryngeal symptoms
seen in several patients but supporting evidence was to
emerge only several years later as technology advanced. The
presence of reﬂuxed material in the extraesophageal areas
suggests it may play a role in causing symptoms from the
larynx and airways, but the growing evidence that pepsin can
cause damage makes the case more compelling.
These insights spurred the development of new tech-
nology to detect reﬂux in the extraesophageal areas. In the
course of these investigations, two ﬁndings emerged almost
as a “byproduct” (hence seemed to attract little notice)
which are likely to change the concept of EER disease. First,
the reﬂuxate loses much of its acidity as it travels upwards
(presumably by neutralisation with bicarbonate in saliva
and from the esophageal mucosal glands) [48, 49]. Second,
r e ﬂ u x a t ec a nb eb o t hl i q u i da n da e r o s o l[ 49–51].
6.2. How Far Up the Esophagus Does Reﬂux Reach? Standard
pHmetry readily detects acid (deﬁned as pH < 4) reﬂuxed
into the lower esophagus by its single sensor stationed 5cm
above the lower esophageal sphincter (LES). Dual pHmetry,
in which the second sensor is stationed in the vicinity of
the upper esophageal sphincter (UES), conﬁrmed proximal
reﬂux does occur [52]. By this time, there was also growing
interestinwhetherreﬂuxatecontaininglesserconcentrations
of acid was potentially damaging. The newly developed
method of combined impedance pHmetry provided the
means to detect liquid reﬂux independent of its pH and to
determine how far proximally such reﬂuxate reaches. The
principle is that ﬂuid is a better electrical conductor than
air, hence impedance (resistance) falls, the higher the acid
concentration, the greater the fall. The catheter has two
pH electrodes, as with dual channel pHmetry (see below),
and six pairs of impedance (resistance) sensors, each pair
comprising two sensors separated by a tiny gap. Just a ﬁlm of
ﬂuid is suﬃcient to bridge this gap and complete the circuit.
In the absence of any ﬂuid, the sensors are exposed to air and
record high impedance.
The pH electrodes are stationed 5cm and 20cm above
the LES, whilst the impedance sensors extend from above
to below the pH electrodes. The resistance sensor detecting
change furthermost from the LES indicates the proximal
reach of reﬂux. These studies have clearly demonstrated
reﬂuxate frequently rises to the proximal esophagus, the
signiﬁcance being it is in a position to reach extraesophageal
areas [53–56]. Investigations in untreated GERD patients
showed 63% of reﬂux episodes were acidic (and 72% of
symptom episodes were associated with acid reﬂux). In
contrast, 80% of reﬂux episodes on PPI were weakly acid or
weakly alkaline (and most symptoms were associated with
reﬂuxate of this nature) [57].
6.3. Acid Reﬂux into the Pharynx. A recent advance is the
development of a nasopharyngeal probe bearing a specially
constructed pH sensor at its end (available as the Dx-
pH probe http://www.restech-corp.com/). The sensor is
stationed in the mid-pharynx (i.e., away from the upper
esophageal sphincter), where it is kept moistened with each
exhaled breath. The environmental pH detected with this
method is ∼5.5; set against this relatively high pH, reﬂux
containing even only little acid is readily detected [50].
6.4. Reﬂux into the Oropharynx and Airways: The Presence
of Pepsin. Pepsin has recently been detected in the saliva
of patients with suspected EER using a highly sensitive
immunoassay which utilises two unique monoclonal anti-
bodies against human pepsin 3 [58] .T h es a m ei m m u n oa s s a y
has detected pepsin in the exhaled breath in patients with
chronic cough thought to be due to EER. The breath sample
is captured, kept cold, and the immunoassay carried out on
the condensate which forms [51].8 International Journal of Otolaryngology
6.5. The Acidity of Reﬂuxate: Its Relevance to EER Disease.
Reﬂuxatedetected in impedance studies is arbitrarily divided
as acid (pH < 4), weakly acid (pH 4–7), and nonacidic
(pH > 7) [59]. Reﬂux at pH <4 is widely regarded as being
damaging to the esophagus because of its high acidity, hence
pH 4–7 is less injurious, and pH >7 probably without eﬀect.
The real signiﬁcance of reﬂuxate containing low or no acid,
however, is that it always contains pepsin, which potentially
can be carried to the extraesophageal areas, where it damages
the epithelium.
As indicated earlier, esophageal damage in typical GERD
is dominated by acid; in contrast, EER disease is mediated
principally by pepsin. This perhaps explains why PPIs fail to
rapidly improve EER disease, unlike their eﬀect in classical
GERD.
6.6. The Physical Form of Reﬂuxate: Liquid and Aerosol . The
concept that reﬂux may also be an aerosol has only recently
emerged, at this stage more plausible (albeit persuasive) than
proven. It arises from detecting acid in the pharynx and
pepsin in the saliva but particularly in the exhaled breath
(see below). Their presence, so far away from the stomach,
is more plausibly explained if they were airborne, that is,
carried in an aerosol, rather than in a column of liquid rising
from the stomach.
Reﬂuxate as an aerosol has several implications. First, as
indicated above, it more plausibly explains the presence of
reﬂuxate deep in the lungs [60, 61] and in the middle ear
in otitis media eﬀusions [62] (where recently bile acids too
have been identiﬁed) [63]. Second, liquid reﬂuxate probably
has higher concentrations of acid and pepsin, but an aerosol
is more likely to carry these damaging agents further into
the extraesophageal areas. Third, their presence conﬁrms
that reﬂuxate has reached. When in excess, and in the
appropriate clinical circumstances, the ﬁndings are arguably
potentially diagnostic of EER. Finally, it draws attention to
a major unmet therapeutic need, namely, the development
of new approaches to more eﬀectively decrease pepsin in
reﬂuxate.
6.7. GER and EER and the Role of the Sphincters: Speculation.
The esophageal lumen is occupied by mucosal folds and air,
both swallowed and reﬂuxed. Impaired LES function results
in excessive reﬂux, and presumably liquid reﬂuxate rises in
the lumen along the mucosal folds. We suggest that the air
in the esophagus provides the medium through which an
aerosol ascends.
The LES in health allows air from the stomach to
be vented whilst minimising the escape of liquids and
semisolids; such separation is less eﬃcient in GERD, where
the sphincter function is impaired. The role of the UES in
reﬂux is less well understood, but we speculate that like the
LES, it too in health can distinguish liquid from gas, holding
back the former and allowing the latter to be vented. We
think, however, it would be diﬃcult to distinguish between
types of gas, air that contains aerosol reﬂuxate from air that
does not. Hence, both are vented and reﬂuxate reaches the
extraesophageal areas.
7.DetectingExtraesophageal Reﬂux
7.1. Diagnosis: A Note. Whilst it is beyond the scope of this
paper to consider the issues surrounding the diagnosis of
EER in any detail, we would like to highlight the following.
7.2. Clinical Manifestations of EER. Today, EER is increas-
ingly considered as a potential cause of symptoms in adults
with chronic problems arising from the larynx, throat, and
airways. Changes are often seen in the larynx, but there is no
feature characteristic of damage by EER. Furthermore, EER
when present may be one of several contributory factors, for
example, smoking.
7.3. Technology Currently Available. Impedance pHmetry
clearly identiﬁes liquid reﬂux and indicates how far proxi-
mally it reaches. Here, it is assumed that liquid is poised to
penetrate into the extraesophageal areas hence EER can be
inferred. Conventionally, one looks to correlation between
proximal reﬂux episodes and symptoms as evidence of a
causative link; but bearing in mind that even infrequent
episodes of EER can be damaging, the absence of such cor-
relation does not necessarily exclude reﬂux-related damage.
Impedance pHmetry (MIIpH) has given us remarkable
insights into the pathophysiology of gastroesophageal reﬂux;
itreadilydetectsliquidreﬂuxateirrespectiveofitspH(hence,
it is particularly useful when investigating patients already
on PPI) and can determine how often and how far up the
esophagus the reﬂuxate reaches—but not beyond it (as yet),
nor can it, as currently conﬁgured, identify aerosol reﬂux. To
d e t e c tE E R ,t h e r e f o r e ,w es u g g e s ti t sr o l ei sm o r es u p p o r t i v e
than diagnostic.
7.4. Emerging Technologies: Acid and Pepsin in the Pharynx,
Saliva and Breath. Aerosol acid reﬂux into the pharynx
can today be detected by the Dx-pH nasopharyngeal probe
(ResTech).Diagnosticcriteriahavebeendeveloped,andapH
level <5 . 5i sr e g a r d e da sa b n o r m a l[ 50].
Pepsin immunoassay now makes it possible to detect
minute amounts of the enzyme in saliva and in exhaled
breath. It has recently been adapted as a lateral ﬂow-based
test (PeptestTM, RD BioMed Ltd., UK), easy to use, with a
detection lower limit of 16ng/mL, and with results available
within minutes. The sensitivity is only slightly lower than
with conventional ELISA, which is laborious and more
timen consuming. The test is noninvasive and will prove
more acceptable to patients, particularly if serial assays are
clinically required. Determining its clinical usefulness in
diagnosis andinmonitoring treatmentwill,however,require
more extensive studies.
Venting air is normal and with it a tiny amount of
aerosolised gastric content is likely to escape, hence the
asymptomatic may have pepsin detectable in the saliva. How
should such a ﬁnding be interpreted? Lessons learnt two
decades ago of the diagnosis of GER by pHmetry give guid-
ance. Some reﬂux of acid into the esophagus is physiological
andnotassociatedwithanysymptoms;thatis,itisthenorm.
Symptoms (with or without erosive esophageal damage)
develop only when reﬂux is excessive. Thus, the diﬀerence
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the degree of acid reﬂux. The same model may apply to
detectingpepsininthesaliva.Thetestisquantitative;wemay,
therefore, ﬁnd that as with GER it is the quantity of pepsin
in extraesophageal areas that correlates best with disease (as
opposed to the presence of a tiny amount).
8. Medical Therapy
8.1. The Place of PPIs. PPIs, dramatically eﬀective in typical
reﬂux, are rather less so in EER. Several clinical trials and
meta-analyses have failed to show clear beneﬁt in LPR [64]
other than one single study that observed a beneﬁt of twice
daily PPI for LPR symptoms and signs [65]. Patients with
asthma when considered as a group showed no discernible
beneﬁt with PPIs; the subset with GER symptoms, however,
were helped [66] but, interestingly, not those with pHmetry-
proven reﬂux alone (in the absence of GER symptoms) [67].
PatientswithchroniccoughinwhomEERwassuspectedalso
did not beneﬁt [68, 69].
Tenatoprazole, a new PPI with a much longer half-life
than those currently available, correspondingly suppresses
acid for a longer period in the 24 hours [33]. Other PPIs
and potassium-competitive acid blockers are in development
[5, 6]. These may prove helpful in patients with typical reﬂux
when currently available PPIs give insuﬃcient response; but
for the reasons stated earlier, they are unlikely to make much
diﬀerence in EER.
Nevertheless, the occasional patient does show improve-
ment, generally partial, with PPIs. In the absence of really
eﬀective treatment, such anecdotes encourage continued
widespread use of profound acid inhibition.
8.2. Antipepsins. Drugs with antipepsin activity have been
used in several clinical studies in patients with peptic ulcer
but were found not to be eﬀective. Examples are amylopectin
sulphate [70–72] and pepstatin [73].
8.3. Alginates: “Sieving Pepsin” from Gastric Secretion. Algi-
nates, widely available for almost 40 years, have recently
been shown to have a powerful eﬀect on pepsin and bile
in reﬂuxate in vitro [74] and potentially oﬀer an eﬀective
treatment [75].
Recent in vitro studies conﬁrm that Gaviscon Advance
(GA), a speciﬁc alginate formulation, removes ∼90% of
pepsin and bile in the ﬁrst “reﬂux episode”, declining to
about 50% by the tenth. Their rate of depletion was similar,
suggesting a common mechanism, most probably selective
binding [74].
8.4.Alginates:EﬀectivenessinEER? Onlyafewstudieshaveas
yet been done, mainly in LPR, and give encouraging results.
8.4.1. LPR. A UK study assessed the beneﬁt of adding
GA to standard vocal hygiene advice (control group) [75]
and a USA investigation on the outcome of adding GA to
preexisting PPI therapy [76]. In both, a dose of 10mL × 4
daily was used; this is the recommended dose when the drug
is used for dyspepsia and is generally used only for short
periods (4 to 8 weeks) but for the trials treatment was given
for six months.
Allocation to treatment in the UK study was randomised
and blinded. The outcome was assessed by those unaware
of the patients’ treatment group. Two scoring instruments
were used, both validated and semiquantitative. The reﬂux
symptomindex(RSI)measuresthesymptomburdenandthe
reﬂux ﬁnding score (RFS) the degree of change observed on
endoscopic examination.
The baseline scores were similar in both groups. RSI
improved signiﬁcantly in the group compared to baseline
both at 2 and 6 months, but the improvement was much
greaterforthoseonGA.TreatmentwithGAgaveasigniﬁcant
improvement in RSI compared to the control group at 2 and
6 months. The RFS did not change in the control group but
improved signiﬁcantly in the GA-treated group but only at
six months; this suggests that endoscopic improvement lags
behind symptom relief [75].
The USA study [76] used both RSI and RSF and, in
addition, a voice-related quality of life index (QLI). Both
treatmentgroupshadsimilarRSIsymptomscoresatthestart
(comparable to that in the UK study) and similar degree of
improvement at two months. Thereafter, however, there was
no further symptom improvement in those on PPI alone,
whereasthegrouponPPI+GAcontinuedtomakegains,the
diﬀerences being signiﬁcant at 4 and 6 months. This change
in symptom intensity was also reﬂected in the RFS and QLI.
8.4.2.ChronicCough. EERisoftensuspectedinpatientswith
chroniccough.Itis,therefore,surprisingthatnomajorstudy
has explored the value of using GA in this group.
8.5. Alginates: Reengineering the Polymer? Alginates are hy-
drocolloids of vegetable origin and are a structural compo-
nent of marine brown algae to which it gives strength and
ﬂexibility. These hydrocolloids are polymers and have the
property of forming gels, ﬁlms, thickeners, and stabilisers.
The polymer is composed of two monomers, mannuronate
and guluronate, and diﬀerences in the properties of alginates
are determined by their ratio. Added calcium binds to
speciﬁc sites and stiﬀens the overall structure.
Theremarkablepropertiesofthesenaturalpolymerscan,
we suggest, be enhanced by modern polymer chemistry,
making it possible to develop derivatives with more powerful
and speciﬁc actions.
8.6.FocusingonPepsinatSourceandatTarget. Thetreatment
of EER today is as we were circa 1970 for the treatment
of peptic ulcer: the need to reduce acid secretion power-
fully was increasingly recognized, but the only drugs then
available were antacids (the use of anticholinergics, which
also reduced acid secretion, restricted by their side eﬀects).
Today, we increasingly recognise the importance of pepsin;
alginates help—but eﬀective treatment will probably require
substantial if not profound suppression of pepsin secretion
(as was achieved for acid with the H2RAs initially and then
with PPIs).
Pepsinogen is secreted by the gastric peptic cells. A
great deal is known about the intricate physiology of acid
secretion from the parietal cells but not nearly as much
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reduce the secretion of this proenzyme at the cellular level
requires deeper understanding of mechanisms and probably
the development of speciﬁc inhibitors: this, we suggest, is an
avenue for the future.
Minimising or halting the damage caused when the
enzyme is adherent to the extraesophageal epithelium and
positioned to be endocytosed requires a diﬀerent strategy
[37, 39]. Hence, the development of an irreversible pepsin
inhibitor has recently been mooted.
We speculate that these two strategies, if and when
developed, are likely to be used together in troublesome
EER disease, the irreversible inhibitor against pepsin already
adherent, and a secretion inhibitor to markedly reduce
pepsinogen secretion and hence pepsin at source, thereby
preventing further damage.
8.7. Surgery. Antireﬂux surgery for GERD gives very good
results in the majority of patients who are carefully selected
for this operation, and extensive clinical and trial experience
has deﬁned its role in patient management. Because gastroe-
sophageal reﬂux is at the root of both GERD and EER, it
is tempting to presume antireﬂux operation will also give
similar beneﬁt in extraesophageal reﬂux. There are indeed
anecdotal instances where operation has helped individual
patients but as yet this cannot be generalized, for there are
substantial diﬀerences between the two conditions.
There are as yet no speciﬁc selection criteria with which
to identify those with EER who are likely to beneﬁt from
surgery. The development of such criteria for GERD and the
optimisationofantireﬂuxsurgerydevelopedoverthelasttwo
decadesofthe20thcentury.Itislikelytotakeseveralyearsfor
a similar position to be reached for the surgical treatment of
EER.
9. Conclusion
Knowledge of GERD emerged in the last third of the 20th
century, as growth accelerating after the development of
PPIs, which triggered many studies on the pathophysiology
and dominated treatment. Knowledge of EER, a part of
the reﬂux spectrum but with distinct characteristics, is still
emerging and, like GERD, may prove to be a worldwide
problem.
The presence of excessive acid in the esophagus is crucial
for the development of GERD symptoms and mucosal
damage, hence the beneﬁt of PPIs which selectively and
profoundly inhibit it. When extended to EER, however,
the results are poor. Emerging knowledge now provides a
persuasive explanation: EER is much more dependent on
pepsin-mediateddamageinthelaryngealandairwaymucosa
than with acid.
Itwastherecognitionthatacidmightplayamajorrolein
peptic ulcer which led to the development of the H2RA and
subsequentlytoPPIs,therealpowerofwhichwastobefound
in GERD, where profound acid reduction is important. We
believe the recognition now of the crucial role of pepsin in
EER may, in turn, stimulate the development of drugs which
speciﬁcally target this molecule. This may radically enhance
our knowledge and management of this condition.
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